An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Romosozumab (Primary) ; Teriparatide
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms STRUCTURE
- Sponsors Amgen
- 20 Mar 2018 Results evaluating P1NP as an early indicator of Bone Mineral Density response presented at The 100th Annual Meeting of the Endocrine Society
- 31 Jul 2017 Results published in The Lancet.
- 17 Apr 2016 Results presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases